Welcome to our dedicated page for OBSV news (Ticker: OBSV), a resource for investors and traders seeking the latest updates and insights on OBSV stock.
ObsEva SA (OBSV) is a clinical-stage biopharmaceutical company pioneering novel therapies for women's reproductive health challenges. This comprehensive news hub provides essential updates on their therapeutic pipeline, clinical milestones, and strategic initiatives.
Investors and healthcare professionals will find timely information about linzagolix development progress, including regulatory submissions and trial data analysis. The resource also covers partnership announcements, financial updates, and scientific presentations relevant to uterine fibroid treatments and endometriosis care.
Key content areas include detailed reports on Phase 3 clinical trial outcomes, FDA/EMA regulatory communications, intellectual property developments, and market access strategies. All information is sourced directly from company filings and verified medical publications to ensure accuracy.
Bookmark this page for structured access to ObsEva's latest advancements in GnRH antagonist research and women's health solutions. Check regularly for updates on their mission to transform reproductive medicine through targeted therapeutic innovation.
ObsEva SA (NASDAQ: OBSV), a biopharmaceutical company focused on women’s reproductive health, will participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 8:40 AM ET. The management will engage in a fireside chat and one-on-one investor meetings. Interested parties can access the presentation via a live webcast.
ObsEva is developing innovative therapies aimed at conditions such as endometriosis, uterine fibroids, and preterm labor, enhancing women's health outcomes.
ObsEva SA (NASDAQ: OBSV / SIX: OBSN) announced a board decision on February 10, 2021, to increase its share capital from 69,629,347 to 81,220,471 shares. This includes the issuance of 11,591,124 new shares priced at 1/13 of a Swiss Franc, with 3,406,480 shares registered from conditional capital. The new shares will be fully subscribed by ObsEva USA Inc. and listed on the SIX Swiss Exchange around February 18, 2021. This move is aimed at providing additional treasury shares for future fundraising and equity plans.
ObsEva SA, a biopharmaceutical company focused on women’s reproductive health, announced a corporate update on February 10, 2021. Major milestones include the regulatory submission of Yselty® for uterine fibroids in the EU and planned NDA filing in the US. The PROLONG Phase 2a study of ebopiprant showed promise in delaying delivery in preterm labor. Key objectives for 2021 involve submitting drug applications and maintaining development timelines for trials targeting various conditions. The company aims to enhance their market position and seeks partnerships to maximize asset value.
ObsEva SA (NASDAQ: OBSV) has approved an increase in its share capital from 60,202,619 to 66,222,867 by issuing 6,020,248 new shares at a price of 1/13 Swiss Franc each. The new shares will be fully subscribed by ObsEva USA Inc., a wholly owned subsidiary, and listed on the SIX Swiss Exchange around February 2, 2021. This move aims to provide treasury shares for future fundraising and equity plans. ObsEva develops therapeutics for women's reproductive health, focusing on endometriosis and related conditions.
ObsEva announced key updates regarding its Yselty program for women’s reproductive health. The European Medicines Agency (EMA) has validated the Marketing Authorization Application for Yselty to treat uterine fibroids, based on data from the Phase 3 PRIMROSE 1 and PRIMROSE 2 studies. Additionally, the Phase 3 EDELWEISS 3 trial for endometriosis is on track, with results expected in 4Q 2021. However, the EDELWEISS 2 study in the U.S. was discontinued due to enrollment challenges, although no safety concerns were reported.
ObsEva SA (NASDAQ: OBSV) has announced its participation in the JP Morgan Virtual Healthcare Conference scheduled from January 11-14, 2021. The company will present on January 14, 2021, at 7:30 a.m. ET. The webcast of the presentation will be accessible on ObsEva's website under the 'Investors' section. ObsEva focuses on developing therapies for women’s reproductive health, with a late-stage pipeline addressing conditions like endometriosis and preterm labor. For more details, visit www.ObsEva.com.
ObsEva SA announced the appointment of David Renas as Chief Financial Officer (CFO), effective January 4, 2021. Renas brings over 30 years of experience, including 15 years in the pharmaceutical industry. He aims to strengthen investor relations as the company prepares to file a New Drug Application (NDA) in the first half of 2021 for Yselty, targeting heavy menstrual bleeding and pain from uterine fibroids. ObsEva recently submitted a Marketing Authorization Application (MAA) for Yselty to the European Medicines Agency (EMA).
ObsEva SA announced positive topline results from the PRIMROSE clinical trials for Yselty (linzagolix), focusing on its efficacy and safety in treating heavy menstrual bleeding due to uterine fibroids. The PRIMROSE 1 trial revealed that 56.4% of women taking the 100 mg dose and 89.3% taking the 200 mg dose with add-back therapy experienced significant bleeding reduction at 52 weeks. Additionally, PRIMROSE 2 data showed sustained pain reduction and bone mineral density recovery. ObsEva plans to submit a New Drug Application to the FDA in 1H2021.
ObsEva SA announced that Dr. Ernest Loumaye will speak at the ISGE 19th World Congress from December 2-5, 2020. His presentation titled The use of a novel oxytocin receptor antagonist, nolasiban, prior to embryo transfer: does it help? will be available on-demand on December 4 at 08:00 am GMT for four months. ObsEva focuses on enhancing women’s reproductive health with a late-stage clinical pipeline targeting disorders like endometriosis and preterm labor. The company trades under the ticker symbol OBSV on Nasdaq.
ObsEva has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency for YSELTY® (linzagolix) to treat heavy menstrual bleeding (HMB) associated with uterine fibroids. This marks a significant milestone after over five years of development. Linzagolix offers flexible dosing options: 100 mg daily without hormonal add-back therapy, 200 mg daily with therapy for long-term use, and short-term 200 mg for quick reduction in fibroid volume. Both Phase 3 trials have met their success criteria, demonstrating effective HMB management.
